| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 31
| Issue : 1 | Page : 26-30 |
|
|
Effect of sertraline and fluvoxamine on quality of life in patients with obsessive–compulsive disorder: A 12-week interventional study
Jasmine Brar, Ajeet Sidana, Nidhi Chauhan, Manoj Kumar Bajaj
Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India
Correspondence Address:
Dr. Nidhi Chauhan
Department of Psychiatry, Government Medical College and Hospital, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ipj.ipj_133_21
|
|
|
Background: Obsessive–compulsive disorder (OCD) is associated with poor quality of life (QoL) and functionality. Treatment leads to improvement in QoL and better functioning. Aim: To assess the effect of treatment with SSRIs on QoL and disability in first-episode, drug-naïve patients with OCD. Materials and Methods: Fifty first-episode, drug-naïve patients with a diagnosis of OCD according to the Diagnostic and Statistical Manual 5 were assessed for severity of illness (Y-BOCS), World Health Organization QoL (WHO-QoL Bref), and disability (WHODAS 2.0) at baseline and at 12 weeks after receiving treatment with either sertraline or fluvoxamine. Results: The scores for QoL were low and for disability were high at baseline, and the scores for WHO-QoL-Bref and WHODAS 2.0 improved significantly after 12 weeks of treatment compared to baseline. This improvement correlated with reduction in the illness severity scores on Yale-Brown Obsessive–Compulsive Scale. The responders to treatment had better QoL and lower disability compared to nonresponders. Conclusion: There is an impairment in QoL and disability in first-episode, drug-naïve patients with OCD, and QoL improves and disability decreases with adequate treatment with SSRIs, and this improvement correlates with improvement in the illness severity.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
